• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Immunotherapy vs Chemoimmunotherapy in Older Adults With Advanced NSCLC

byDaniel GoldshteinandSze Wah Samuel Chan
March 25, 2024
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR.

2. Grade 3 or higher immune-related adverse events occurred in 24.3% and 17.9% in the ICI-chemotherapy and ICI-alone groups.

Evidence Rating Level: 2 (Good)

Study Rundown: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in non-small cell lung cancer (NSCLC), with pembrolizumab showing promise in older adult populations based on pooled analyses and cohort studies. However, the efficacy and safety of combining ICIs with chemotherapy in older NSCLC patients remain uncertain, with previous analyses failing to demonstrate an overall survival benefit in patients aged 75 and older. This retrospective study evaluated combination ICI-chemotherapy in older NSCLC patients. The collected endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. The review found that 28% received ICI-chemotherapy combination treatment (median OS was 20.0 months, median PFS was 7.7 months), and 34% received ICI alone (OS 19.8, PFS 7.7). Stratifying by PD-L1 score, the HR for median OS was 0.91 (non-significant) in ≥50% PD-L1, and HR 0.79 (non-significant) in 1%-49% PD-L1. With regards to safety, grade 3 or higher immune-related adverse events occurred in 24.3% and 17.9% in the ICI-chemotherapy and ICI-alone groups, respectively (p=.03). Grade 3 and higher myelosuppression was similar in the ICI-chemotherapy and platinum-doublet chemotherapy groups. The strengths of this study include its subgroup analysis and size of participants, and the limitations include its retrospective nature and its single ethnicity cohort. Overall, this study found that ICI-chemotherapy combination treatment had similar survival compared with ICI alone in patients 75 years and older with an increased incidence of adverse events.

Click to read the study in JAMA

Relevant Reading: Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

RELATED REPORTS

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

In-Depth [retrospective cohort]: This multicenter study conducted in Japan reviewed records of adults over the age of 75 who had stage IIIB or above NSCLC (n = 1245), EGFR mutations were excluded. The median follow-up duration was 19.2 months. The review found that 28% received ICI-chemotherapy combination treatment (median OS was 20.0 months [95%CI, 17.1-23.6], median PFS was 7.7 months [95%CI, 6.5-8.7]), 34% received ICI alone (OS 19.8 [95%CI, 16.5-23.8], PFS 7.7 [95%CI, 6.6-8.8]), 25% received platinum-doublet chemotherapy (OS 12.8 [95%CI, 10.7-15.6], PFS 5.4 [95%CI, 4.8-5.7]), and 12% received single-agent chemotherapy (OS 9.5 [95%CI, 7.4-13.4], PFS 3.4 [95%CI, 2.6-4.0]). Stratifying by histology, the HR for median OS was 1.03 (95%CI, 0.78-1.37) when comparing ICI-chemotherapy vs ICI alone in adenocarcinoma, and HR 0.79 (95%CI, 0.57-1.09) in squamous cell carcinoma. Stratifying by PD-L1 TPS, the HR for median OS was 0.91 (95%CI, 0.62-1.34) in ≥50% PD-L1 TPS, and HR 0.79 (95%CI, 0.55-1.14) in 1%-49% PD-L1 TPS. With regards to safety, grade 3 or higher immune-related adverse events occurred in 24.3% and 17.9% in the ICI-chemotherapy and ICI-alone groups, respectively (p=.03). Grade 3 and higher myelosuppression was similar in the ICI-chemotherapy and platinum-doublet chemotherapy groups. Overall, this study found that ICI-chemotherapy combination treatment had similar survival compared with ICI alone in patients 75 years and older with an increased incidence of adverse events.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: geriatric oncologylung cancerPembrolizumab
Previous Post

A cell-free, blood-based DNA screening test for colorectal cancer compared to colonoscopy

Next Post

Conservative oxygenation improves outcomes in critically ill children on invasive ventilation

RelatedReports

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 4, 2025
Patient Basics: Lung Cancer Overview
Chronic Disease

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 2, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Next Post

Conservative oxygenation improves outcomes in critically ill children on invasive ventilation

#VisualAbstract: Paclitaxel-coated balloon may be superior to uncoated balloon for coronary in-stent restenosis

#VisualAbstract: Bariatric surgery may provide superior long-term glycemic control compared to medical management in patients with type 2 diabetes

Preterm infants responsive to PCV13 vaccine

Typhoid conjugate vaccine shows promising long-term efficacy in children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.